[go: up one dir, main page]

MX2017006858A - Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol. - Google Patents

Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol.

Info

Publication number
MX2017006858A
MX2017006858A MX2017006858A MX2017006858A MX2017006858A MX 2017006858 A MX2017006858 A MX 2017006858A MX 2017006858 A MX2017006858 A MX 2017006858A MX 2017006858 A MX2017006858 A MX 2017006858A MX 2017006858 A MX2017006858 A MX 2017006858A
Authority
MX
Mexico
Prior art keywords
pharmaceutical
weight
ethanol
influence
nutraceutical composition
Prior art date
Application number
MX2017006858A
Other languages
English (en)
Inventor
JOSHI Shraddha
Jain Vinay
GUHA Ashish
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of MX2017006858A publication Critical patent/MX2017006858A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

La invención se refiere a una composición farmacéutica o nutracéutica, que comprende a) un núcleo a), que comprende un ingrediente activo farmacéutico o nutracéutico y b) una capa b) de recubrimiento, que comprende una mezcla de 80 a 96% en peso de un polímero de (met)acrilato insoluble en agua y de 4 a 20% en peso de goma guar, en donde el polímero de (met)acrilato insoluble en agua se compone de unidades polimerizadas de más de 95 y hasta 100% en peso de ésteres de alquilo C1 a C4 de ácido acrílico o de ácido metacrílico y menos de 5% en peso de ácido acrílico o ácido metacrílico.
MX2017006858A 2014-11-26 2015-11-23 Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol. MX2017006858A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5930CH2014 2014-11-26
PCT/EP2015/077302 WO2016083278A1 (en) 2014-11-26 2015-11-23 Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol

Publications (1)

Publication Number Publication Date
MX2017006858A true MX2017006858A (es) 2017-11-15

Family

ID=54697570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006858A MX2017006858A (es) 2014-11-26 2015-11-23 Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol.

Country Status (14)

Country Link
US (1) US10111838B2 (es)
EP (1) EP3223797B1 (es)
JP (1) JP6695337B2 (es)
KR (1) KR20170086044A (es)
CN (1) CN107072957B (es)
BR (1) BR112017011198A2 (es)
CA (1) CA2967722A1 (es)
ES (1) ES2786312T3 (es)
HU (1) HUE049247T2 (es)
IL (1) IL251626A0 (es)
MX (1) MX2017006858A (es)
PL (1) PL3223797T3 (es)
SI (1) SI3223797T1 (es)
WO (1) WO2016083278A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020223A1 (it) * 2002-02-07 2003-08-07 Claudio Frulla Apparecchiatura per la realizzazione di oggetti in alluminio leghe dialluminio leghe leggere e simili
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20200289423A1 (en) * 2017-09-14 2020-09-17 Evonik Operations Gmbh Polymer and dosage form with sustained release properties and resistance against the influence of ethanol
JP2021515778A (ja) * 2018-03-09 2021-06-24 エボニック オペレーションズ ゲーエムベーハー エタノールの影響に対する耐性を有するポリマー混合物
BR112020023982A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CN108836948B (zh) * 2018-06-11 2024-04-12 宁波西敦医药包衣科技有限公司 一种利用包衣技术实现营养素可控制释放的产品
RS61368B1 (sr) * 2018-09-27 2021-02-26 Inibsa Ginecologia S A Postupak za pripremu višejediničnog oralnog doznog oblika sa modifikovanim oslobađanjem doksilamin sukcinata i piridoksin hidrohlorida
CN109472445B (zh) * 2018-09-29 2022-04-26 成都理工大学 冰水泥石流的危险性判断方法及其应用
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CN116396432B (zh) * 2023-03-08 2025-07-04 郑州郑氏化工产品有限公司 一种种衣剂用成膜剂及其制备方法、应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8702411D0 (en) 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
CA2234936C (en) * 1998-04-17 2004-06-29 Glucogenics Pharmaceuticals Inc. Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
DE10011447A1 (de) 2000-03-10 2001-09-20 Roehm Gmbh Dispersion mit nichtionischem Emulgator
DE102004011349A1 (de) 2004-03-05 2005-09-22 Basf Ag Wässrige Polymerdispersion auf Basis von Alkyl(meth)-acrylaten
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
RS20070512A (sr) 2005-06-29 2009-01-22 Panacea Biotec Ltd., Farmaceutske kompozicije sa zadržanim otpuštanjem i postupci za njihovo dobijanje
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
WO2012166474A1 (en) 2011-06-01 2012-12-06 Fmc Corporation Controlled release solid dose forms
WO2012171884A1 (en) * 2011-06-17 2012-12-20 Evonik Röhm Gmbh Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
EP2720682B1 (en) * 2011-06-17 2016-11-23 Evonik Röhm GmbH Coating composition suitable for pharmaceutical or nutraceutical dosage forms
CN102727420B (zh) * 2012-06-27 2014-01-01 深圳翰宇药业股份有限公司 D-谷氨酰-d-色氨酸钠结肠定位释药制剂及其制备方法

Also Published As

Publication number Publication date
IL251626A0 (en) 2017-06-29
EP3223797B1 (en) 2020-02-26
CA2967722A1 (en) 2016-06-02
WO2016083278A1 (en) 2016-06-02
BR112017011198A2 (pt) 2018-06-26
EP3223797A1 (en) 2017-10-04
US20170304211A1 (en) 2017-10-26
ES2786312T3 (es) 2020-10-09
JP6695337B2 (ja) 2020-05-20
US10111838B2 (en) 2018-10-30
PL3223797T3 (pl) 2020-07-27
SI3223797T1 (sl) 2020-06-30
CN107072957B (zh) 2021-01-29
HUE049247T2 (hu) 2020-09-28
CN107072957A (zh) 2017-08-18
KR20170086044A (ko) 2017-07-25
JP2018502064A (ja) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2017006858A (es) Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol.
MX376383B (es) Composicion farmaceutica o nutraceutica con resistencia contra la influencia del etanol
MX347227B (es) Composicion farmaceutica o nutraceutica con liberacion sostenida caracteristica y con resistencia contra la influencia del etanol.
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
MX355662B (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influencia de etanol.
MX2016010437A (es) Composicion farmaceutica o nutraceutica con caracteristica de liberacion sostenida y con resistencia contra la influencia del etanol.
WO2015075557A3 (en) C/ebp alpha short activating rna compositions and methods of use
CL2016002308A1 (es) Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer
EP4620520A3 (en) Methods and compositions relating to chondrisomes
AR128816A2 (es) Formas de dosificación farmacéutica de perlas de cisteamina
MX2013014142A (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol.
WO2015196146A3 (en) Rna-based compositions and adjuvants for prophylactic and therapeutic treatment
GEAP202114677A (en) Orodispersible dosage unit containing an estetrol component
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
SG11201912612WA (en) Composition comprising a multistage polymer and a (meth) acrylic polymer, its method of preparation and its use
MX2018005415A (es) Composicion formadora de pelicula dental duradera y usos de esta.
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
WO2016089206A3 (en) Selective il-6-trans-signalling inhibitor compositions
BR112016025501A2 (pt) composição de revestimento
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
MX2015010449A (es) Composicion farmaceutica multiparticulada que comprende una multitud de dos clases de granulos.
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
IN2014DN06965A (es)
WO2016186349A3 (ko) 사군자 추출물을 함유하는 전립선 비대증 예방 또는 치료용 조성물
CO7160088A2 (es) Polímeros hidrófilos con bajo contenido de ácido como estabilizadores para emulsiones a base de agua